Participant flow

Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · Source last updated 2019-08-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive DLI IV. Treatment repeats every 4-8 weeks for 5 doses in the absence of disease progression or unacceptable toxicity. therapeutic allogeneic lymphocytes: Given IV laboratory biomarker analysis: Correlative studies

   id

   FG000

   title

   Treatment (DLI)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         17

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         12

      type

      Relapse

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      GVHD

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Graft Failure

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         77

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         36

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         41

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice